Skip to main content
Not Found
Live Webinar

2-Day Psychedelic Integration: Premise & Promise

Average Rating:
Not yet rated
Elizabeth Nielson, PhD |  Ingmar Gorman, PhD |  Jeffrey Guss, MD |  Alexander Camargo, PsyD
2 Full Days
Product Code:
Brochure Code:
Media Type:
Live Webinar

Schedule at a glance


The official foundational 2-day training course for therapists who want to learn about Psychedelic Harm Reduction and Integration in clinical practice developed by and co-sponsored by Fluence Training.

Psychedelic compounds have a rich and fascinating history of use in spiritual and healthcare settings. After a nearly 60-year hiatus, recent advances in clinical research indicate that these medicines may soon be available to the public as treatments for some of humanity’s most profound forms of suffering: alcoholism, drug addiction, PTSD, and depression. Psychotherapists and other healthcare providers are increasingly called upon to help clients integrate profoundly meaningful psychedelic experiences into the fabric of their daily lives, resulting in long-term positive changes.

This 2-day training is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This interactive training includes experiential learning, demonstrations, self-reflection, and role-play exercises. The themes of spirituality, ethics, and critical discussion will be woven throughout the program with opportunities for connection, collaboration, and building community.

We start with the premise that your patients are curious about psychedelic research, and so are you! The early part of our program gives the background on psychedelic compounds, their history, and current research with MDMA and Psilocybin-assisted therapy. We then discuss recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment. We then move to the practicalities of defining integration and how it can occur in a clinical setting. We focus on translating research findings into clinical practice, including working with patients who are considering using psychedelics, actually using psychedelics, or have used them in the past. This program includes discussion of assessment and integration techniques, resources, and legal and ethical issues. Program participant clinicians will complete the retreat with a conceptual and practical understanding of how to engage clients in discussions about psychedelics that are balanced, reduce potential for harm, and increase the potential for benefit from these experiences. 


CE Information Coming Soon

Continuing education credit information is coming soon for this non-interactive self-study package.

CEs may be available for select professions, as listed in the target audience. Hours will be dependent on the actual recording time. Please check with your state licensing board or organization for specific requirements. 

There may be an additional fee for CE certificates. Please contact our Customer Service at 1-800-844-8260 for more details. 

**Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of mental health professionals. As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice in accordance with and in compliance with your professions standards.


Elizabeth Nielson, PhD's Profile

Elizabeth Nielson, PhD Related seminars and products

Dr. Elizabeth Nielson, PhD, is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.


Speaker Disclosures:
Financial: Elizabeth Nielson is the co-founder of Fluence and has employment relationships with Columbia University Irving Medical Center, New York State Psychiatric Institute, and MAPS NY Private Practice Research Site. She receives a speaking honorarium from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Elizabeth Nielson is the founding member and an advisory board member of the Psychedelic Medicine Association. She is a member of the American Psychological Association and the International Society for Research on Psychedelics.

Ingmar Gorman, PhD's Profile

Ingmar Gorman, PhD Related seminars and products

Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist and supervisor on the same study. He is co-author on a Nature Medicine paper reporting the results of the first Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Dr. Gorman has also published on the topics of classic psychedelics, ketamine, and Psychedelic Harm Reduction and Integration.

Speaker Disclosures:
Financial: Dr. Ingmar Gorman is the co-founder of Fluence and the co-principal investigator and study therapist, MAPS-Sponsored Phase 2/3 MDMA-Assisted Psychotherapy Clinical Trials. He receives royalties as a published author. Dr. Gorman receives a speaking honorarium from Psychotherapy Networker and PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Ingmar Gorman has no relevant non-financial relationships.

Jeffrey Guss, MD's Profile

Jeffrey Guss, MD Related seminars and products

Jeffrey Guss, MD, is a psychiatrist, psychoanalyst, researcher and teacher with specializations in psychoanalytic therapy and psychedelic therapy. He is on the faculty of the NYU Postdoctoral Program in Psychotherapy and Psychoanalysis and is a Clinical Assistant Professor of Psychiatry at NYU School of Medicine.

Dr. Guss was the Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU study on psilocybin-assisted psychotherapy in the treatment of cancer anxiety and is a study therapist with several MAPS studies. He has published on the integration of Acceptance and Commitment Therapy with psychedelic assisted therapy for MDD in Journal of Contextual and Behavioral Science and co-authored a paper on the influence of therapists’’ firsthand psychedelic experiences. He maintains a private practice in New York City.


Speaker Disclosures:
Financial: Dr. Jeffrey Guss is a lead trainer with Fluence. He has employment relationships with California Institute for Integral Studies, Yale University, and Cybin. Dr. Guss maintains a private practice. He receives a speaking honorarium from PESI, Inc.
Non-financial: Dr. Jeffrey Guss is a study therapist with the New York University Medical Center Research and is a sub-investigator in MAPS.

Alexander Camargo, PsyD's Profile

Alexander Camargo, PsyD Related seminars and products

Alexander Camargo, PsyD, is a psychologist based in New York City and maintains a private practice in Manhattan. His work is heavily influenced by psychoanalytic and attachment theories. In addition, he provides psychedelic harm reduction and integration, helping clients prepare for psychedelic experiences, incorporate insights or cope with challenges post-experience.

Speaker Disclosures:
Financial: Dr. Alexander Camargo maintains a private practice and has employment relationships with New York State Psychiatric Institute, Fluence, and Yeshiva University. He receives a speaking honorarium from Psychotherapy Networker and PESI, Inc. Dr. Camargo has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Alexander Camargo has no relevant non-financial relationships.

Additional Info

Program Information

Access Period for Live Webcast

For live CE credit, you must watch the live webcast in its entirety at its scheduled time and complete the CE quiz and evaluation within one week. You will have access for 90 days after the program for review.

Webcast Schedule

Please note: There will be a 60-minute lunch and two 15-minute breaks; one in the morning and one in the afternoon. Lunch and break times will be announced by the speaker and at their discretion.


Visit our FAQ page at or contact us at


  1. Analyze the historical justifications for psychedelic clinical research.
  2. Catalogue the key theoretical approaches to psychedelic-assisted therapy.
  3. Evaluate the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients.
  4. Assess the comparison between psychedelic integration psychotherapy to integration in peer and shamanic settings.
  5. Assess clients for key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience.
  6. Utilize principles of psychedelic-assisted therapy in a basic/initial assessment of clients who report psychedelic use.
  7. Categorize contraindications and discuss high risk cases of individuals who are contemplating psychedelic use.
  8. Demonstrate the role of the therapist in an individual's integration psychotherapy process.


  • An Introduction to Psychedelics and Potential Role in Therapeutic Use 
  • Psychedelic Integration- What it is and what it isn’t 
  • Basics of psychedelics and psychedelic science 
  • Past models and theories of psychedelic therapy 
  • Psilocybin for alcohol use disorder- therapy model & implication 
  • MDMA-assisted treatment for PTSD: the latest research 
  • Introducing psychedelic harm reduction in clinical practice 
  • Psychedelic Integration in clinical practice 
  • Harm Reduction Informed Preparation 
  • Psychedelic Harm Reduction/Preparation 
  • Role plays format and instruction 
  • Demonstration of an integration session 
  • Breakout group session to practice post-experience integration 
  • Demonstration of an integration session 
  • Breakout group session to practice post-experience integration 
  • Putting what you’ve learned this weekend into practice 
  • Roleplays, debrief and discussion 

Target Audience

  • Counselors
  • Social Workers
  • Marriage and Family Therapists
  • Psychologists


Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to: PO Box 1000, Eau Claire, WI 54702-1000 or call 1-800-844-8260.

ADA Needs
We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.

Please wait ...

Back to Top